GlassScriptPhysician profile
Julie B Reno
NPI 1366403925
$2,420.04
in general payments reported to CMS, 2019-2025
22 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $95.34 · 2021: $187 · 2022: $424 · 2023: $454 · 2024: $488 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,325.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $424.95 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Novartis Pharmaceuticals Corporation | $314.04 | 2019-2023 | |
| Alcon Vision LLC | $264.18 | 2020-2025 | Rocklatan, Eysuvis, Tryptyr |
| Sun Pharmaceutical Industries INC. | $245.48 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $192.63 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $144.11 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $124.74 | 2023 | Syfovre |
| Oyster Point Pharma, INC. | $114.90 | 2023-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $85.54 | 2019-2021 | |
| Dompe US, INC. | $67.89 | 2021-2025 | Oxervate |
| Abbvie INC. | $66.90 | 2022-2023 | |
| Eyevance Pharmaceuticals LLC | $65.62 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $51.40 | 2020-2023 | Tecnis Iol, Healon Duet Pro |
| Kala Pharmaceuticals, INC. | $45.82 | 2021-2022 | |
| Shire North American Group INC | $44.78 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $43.98 | 2019-2022 | |
| Thea Pharma INC. | $35.47 | 2022-2025 | Iyuzeh |
| Amgen INC. | $20.55 | 2024 | Tepezza |
| Harrow Eye, LLC | $19.78 | 2025 | Vevye |
| Rxsight INC | $16.27 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| New World Medical,INC. | $15.96 | 2022 | |
| Horizon Therapeutics Plc | $15.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Reno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.